7 results about "Fibrotic lesion" patented technology

The application discloses an integrin-targeting peptide-collagenase drug combination and a drug composition constructed by the integrin-targeting peptide-collagenase drug combination. The drug combination can effectively block mechanical signals and biochemical signals mediating fibrosis, efficiently inhibit fibroblast activation, reduce the secretion of extracellular matrix proteins, and reshape the fibrotic microenvironment. Efficient reduction of fibrosis can promote the penetration of subsequent therapeutic drugs, and has a cascade penetration effect. The constructed drug composition can synergistically deliver integrin-targeting peptides and collagenase, and after release, the integrin-targeting peptides and collagenase can synergistically act in the form of free molecules in fibrotic lesions, thereby providing a new strategy for efficient delivery of fibrosis treatment drugs.

The application belongs to the technical field of reversing liver fibrosis, and particularly relates to self-assembled nanoparticles for reversing liver fibrosis and a preparation method and application thereof. The nanoparticles comprise N-acetylmannosamine and 2-(2-propylpyridine-4-yl)-4-(p-tolyl)thiazole. The preparation method comprises the following steps: S1, self-assembly reaction: under stirring, an organic phase solution of 2-(2-propylpyridine-4-yl)-4-(p-tolyl)thiazole is added into an aqueous phase solution of N-acetylmannosamine, the mixed emulsion is continuously stirred, and then ultrasonic treatment is performed on the mixed emulsion to complete self-assembly; and S2, purification: the reaction solution after S1 is allowed to stand, centrifugation is performed to discard the supernatant, and then a washing solution is added into the centrifugal tube to resuspend the centrifugation, and the purified self-assembled nanoparticles are obtained after centrifugation. The application forms a stable nanostructure through intermolecular self-assembly of ManNAC and Fatostatin, realizes efficient enrichment and accurate release at a fibrotic lesion in the liver, and reverses the liver fibrosis process through synergistic regulation of a lipid metabolism axis.

An ultrasound diagnostic apparatus includes an ultrasound transmission and reception unit that transmits and receives ultrasound waves to and from a subject and that generates a reception signal, an ultrasound information generation unit that generates a plurality of types of ultrasound information based on the reception signal, a detection and measurement unit that detects and measures a lesion based on the plurality of types of ultrasound information, and a lesion / risk information analysis unit that analyzes a state of the lesion based on a measurement result obtained by the detection and measurement unit. The detection and measurement unit includes at least one of a set of a tumorous lesion detection unit and a tumorous lesion measurement unit, a set of a fibrotic lesion detection unit and a fibrotic lesion measurement unit, a set of a calcified lesion detection unit and a calcified lesion measurement unit, or a set of a fatty liver detection unit and a fatty liver measurement unit.

This invention belongs to the field of biomedical technology and provides an application of a ferroptosis inhibitor in the treatment of hepatitis. This invention reveals that a GRIM-19 gene defect specifically induces ferroptosis in hepatocytes, rather than other cell death mechanisms such as apoptosis, necrosis, or autophagy. This invention provides a ferroptosis inhibitor with Ferrostatin-1 as the active ingredient, solving the technical problem of insufficient intervention against the ferroptosis mechanism in existing hepatitis treatments. This inhibitor can significantly increase the expression level of GPX4 in liver tissue, effectively clear lipid peroxides, a core toxic product in the ferroptosis process, and block the ferroptosis process; in addition, it can significantly inhibit the activation of the NLRP3 inflammasome and reduce the expression of downstream inflammatory factors, thereby alleviating inflammatory cell infiltration and fibrotic lesions in the liver. This invention is applicable to the treatment of GRIM-19 deficiency-related chronic hepatitis, providing a new strategy for targeted therapy of liver diseases.

Handheld intraoral device to objectively measure mucosal stiffness in OSMF and fibrotic lesions

The present invention relates to the use of compositions comprising specific exosomes secreted by umbilical cord blood mononuclear cells (UCBMNCs) in the prevention and treatment of fibrotic disorders such as fibrotic skin and lung injuries. The exosome compositions of the invention present activity in skin fibrosis and in lung diseases. Moreover, these compositions are also effective in reverting or preventing disease-associated parameters, such of lung diseases, proving its action against respiratory disorders with an inflammatory component, particularly when mediated by macrophages and / or T-cells. Therefore, the present invention lays in the technical domain of pharmaceuticals, medicine, cosmetics, dermo-cosmetics, research and development in cellular biology and appliances thereof.

The invention relates to a gel composition containing pirfenidone, which is advantageous over other cutaneously administered pharmaceutical forms known in the prior art and which can be used in treatment for the restoration of tissues with fibrotic lesions and for the prevention of fibrotic lesions.